KR940008681A - 디클로페낙 염용 비경구 용액 - Google Patents

디클로페낙 염용 비경구 용액 Download PDF

Info

Publication number
KR940008681A
KR940008681A KR1019930021919A KR930021919A KR940008681A KR 940008681 A KR940008681 A KR 940008681A KR 1019930021919 A KR1019930021919 A KR 1019930021919A KR 930021919 A KR930021919 A KR 930021919A KR 940008681 A KR940008681 A KR 940008681A
Authority
KR
South Korea
Prior art keywords
glutathione
acetylcysteine
acid
acceptable
hydroxy
Prior art date
Application number
KR1019930021919A
Other languages
English (en)
Inventor
갈리 브루노
Original Assignee
베르너 발데크
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 에이지 filed Critical 베르너 발데크
Publication of KR940008681A publication Critical patent/KR940008681A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 디클로페낙 및 글루타치온 또는 N-아세틸 시스테인과 결합한 에틸 아세테이트와 같은 안정화제를 포함한 멸균가능한 비경구 용액의 형태로 존재하는 약제학적 조성물에 관한 것이다.

Description

디클로페낙 염용 비경구 용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. a)디클로페낙의 약제학적으로 허용되는 염; b)가용화제로서 1,2-프로필렌 글리콜 또는 폴리에틸렌 글리콜300내지 400; c)글루타치온, C2-3알칸카복실산C2-4알킬 에스테르, 또는 하이드록시 -C2-4알칸카복실산 C2-4알킬 에스테르 또는 N-아세틸시스테인과 결합된 글루타치온 및 C2-3알칸카복실산 C2-4알킬 에스테르, 또는 하이드록시-C2-4알칸카복실산 C2-4알칸카복실산 C2-4알킬 에스테르와 결합한 N-아세틸시스테인 및 d)주사용 제형에 대해 허용되는 담체액체, 경우에 따라, 이에 대해 허용되는 추가 부형제를 포함하는 비경구적으로 투여가능한 주사액의 형태로 존재하는 약제학적 조성물.
  2. 제1항에 있어서, a)디클로로페낙의 나트륨 염; b)가용화제로서 1,2-프로필렌 글리콜 도는 폴리에틸렌 글리콜300; c)안정화제로서 글루타치온 또는 N-아세틸시스테인과 결합된 에틸 락테이트 및 d)주사용 제형에 대해 허용되는 담체 액체, 경우에 따라, 이에 대해 허용되는 추가 부형제를 포함하는 약제학적 조성물의 제조방법.
  3. 담체 액제 d)중 성분 a), b)및 c)를 어더한 목적하는 순서대로 용해시키고,경우에 따라, 주사제형에 허용되는 추가 부형제를 가함을 특징으로 하는, 제1항에 따른 약제학적 조성물의 제조방법.
  4. 디클로페낙의 약제학적으로 허용되는 염의 비경구적 투여용 약제학적 조성물을 제조하는데 있어서, 글루타치온, C2-3알칸카복실산C2-4알킬 에스테르, 또는 하이드록시 -C2-4알칸카복실산 C2-4알킬 에스테르 또는 N-아세틸시스테인과 결합된 글루타치온 및 C2-3알칸카복실산 C2-4알킬 에스테르, 또는 하이드록시-C2-4알칸카복실산 C2-4알칸카복실산 C2-4알킬 에스테르와 결합한 N-아세틸시스테인으로 이루어진 그룹에서 선택한 약제학적으로 허용되는 안정화제의 용도
  5. 사람 또는 동물 신체의 치료적 처리를 위한 방법에서 사용하기 위한 제1항에 따른 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930021919A 1992-10-22 1993-10-21 디클로페낙 염용 비경구 용액 KR940008681A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH03275/92-9 1992-10-22
CH327592 1992-10-22

Publications (1)

Publication Number Publication Date
KR940008681A true KR940008681A (ko) 1994-05-16

Family

ID=4252473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930021919A KR940008681A (ko) 1992-10-22 1993-10-21 디클로페낙 염용 비경구 용액

Country Status (11)

Country Link
US (1) US5389681A (ko)
EP (1) EP0595766A1 (ko)
JP (1) JPH06199662A (ko)
KR (1) KR940008681A (ko)
AU (1) AU4905293A (ko)
CA (1) CA2108820A1 (ko)
FI (1) FI934593A (ko)
HU (1) HUT75684A (ko)
IL (1) IL107353A0 (ko)
NO (1) NO933782L (ko)
ZA (1) ZA937822B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554650A (en) * 1994-07-28 1996-09-10 Southern Research Institute Antiphlogistic, analgesic, antipyretic injection preparation
IT1286778B1 (it) * 1996-11-20 1998-07-17 Alfa Wassermann Spa Capsule contenenti diclofenac o suoi sali in soluzione
DE59712694D1 (de) * 1997-04-18 2006-08-24 Fritz Stanislaus Stabilisiertes arzneimittel enthaltend cysteinylderivate
EP1219304B1 (de) * 2000-12-28 2004-10-20 Fresenius Kabi Austria GmbH Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung
AT413794B (de) * 2002-09-19 2006-06-15 Mayrhofer Pharmazeutika Ges M Pharmazeutische zubereitung von diclofenac-natrium
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
DE602004025151D1 (de) * 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
US8048919B2 (en) * 2004-06-28 2011-11-01 Archer Daniels Midland Company Use of ethyl lactate as an excipient for pharmaceutical compositions
CN101072555B (zh) * 2004-12-08 2011-06-29 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
JP4866546B2 (ja) * 2004-12-10 2012-02-01 久光製薬株式会社 ジクロフェナク含有乳剤性軟膏剤
NZ554779A (en) 2005-02-01 2011-02-25 Troikaa Pharmaceuticals Ltd Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts
MX2007014862A (es) * 2005-05-27 2008-02-21 Panacea Biotec Ltd Composiciones inyectables y procedimiento para la preparacion de dichas composiciones.
KR20160033796A (ko) 2006-03-28 2016-03-28 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
KR20090010953A (ko) * 2006-03-28 2009-01-30 자블린 파머슈티칼스 인코포레이티드 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형
US9211251B2 (en) * 2007-07-30 2015-12-15 Troikaa Pharmaceuticals Limited Injectable preparations of diclofenac and its pharmaceutically acceptable salts
CN102292068B (zh) * 2009-01-30 2013-10-09 克迪斯药品有限公司 双氯芬酸、卡马西平和苄达明的透皮递送
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
JP2014500794A (ja) 2010-11-15 2014-01-16 アーチャー−ダニエルズ−ミッドランド カンパニー 組成物及び汚染物質の変換におけるその使用
CN103781484A (zh) 2011-07-20 2014-05-07 赫思公司 治疗疼痛的方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US20140187635A1 (en) 2012-12-28 2014-07-03 Themis Medicare Limited Diclofenac compositions
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CN103432132B (zh) * 2013-08-31 2015-01-21 西南大学 甲磺酸普立地诺双氯芬酸钠注射液及其制备方法
CN104288096A (zh) * 2014-06-24 2015-01-21 郑州百瑞动物药业有限公司 一种用于治疗奶牛发热及蹄病的注射液及其制备方法
WO2016170401A1 (en) * 2015-04-20 2016-10-27 Umedica Laboratories Pvt. Ltd Novel injectable composition of diclofenac sodium
US11110073B2 (en) 2017-03-24 2021-09-07 Cadila Healthcare Limited Storage stable aqueous injectable solution comprising diclofenac
GR1009729B (el) * 2018-08-02 2020-05-15 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια Σταθερος ενεσιμος συνδυασμος
US11707443B2 (en) 2019-09-26 2023-07-25 Rk Pharma Inc. Storage stable aqueous parenteral solutions comprising diclofenac

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
DE3328401A1 (de) * 1983-08-05 1985-02-21 Merckle GmbH, 7902 Blaubeuren Injizierbare loesung zur behandlung von entzuendungen
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US5079001A (en) * 1989-11-03 1992-01-07 Ciba-Geigy Corporation Liquid oral formulation of diclofenac

Also Published As

Publication number Publication date
FI934593A (fi) 1994-04-23
IL107353A0 (en) 1994-01-25
FI934593A0 (fi) 1993-10-18
NO933782D0 (no) 1993-10-21
NO933782L (no) 1994-04-25
JPH06199662A (ja) 1994-07-19
HU9302985D0 (en) 1994-01-28
AU4905293A (en) 1994-05-05
EP0595766A1 (de) 1994-05-04
ZA937822B (en) 1994-04-22
HUT75684A (en) 1997-05-28
CA2108820A1 (en) 1994-04-23
US5389681A (en) 1995-02-14

Similar Documents

Publication Publication Date Title
KR940008681A (ko) 디클로페낙 염용 비경구 용액
US6960346B2 (en) Vehicles for delivery of biologically active substances
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
KR920019371A (ko) 안정화된 인자 ⅷ 제제
BG106439A (en) Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative
KR890000434A (ko) 신아미노산 유도체, 그 제조방법 및 그를 함유한 약제조성물
TW589188B (en) Protein-free formulations
KR920012113A (ko) 펩타이드 유도체의 사용방법
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
GB2581656A (en) Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
ES2336034T3 (es) Composiciones de diclofenaco inyectables estables.
KR960030948A (ko) 비강투여용 비무기 식염용액
KR970025615A (ko) 암 전이 억제제
KR970706841A (ko) 성장호르몬 및 루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and leucine)
ES2390055T3 (es) Fármaco que contiene ácido(2R)-2-propiloctanoico como principio activo
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
ES2078019T3 (es) Amidas de alcanoil l-carnitina con aminoacidos y composiciones farmaceuticas que las contienen para promover regeneracion del tejido nervioso, inhibir degeneracion neuronal, mejorar el proceso de aprendimiento y memoria y para el tratamiento de coma.
DE60333821D1 (de) Stabilisierte albumin-zubereitungen
KR950024769A (ko) 고농도 tcf 제제
US3230143A (en) Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
BRPI0418005B1 (pt) composição farmacêutica de vinflunina, utilização de uma composição, e, processo de preparação de uma composição
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
KR910018348A (ko) 술포닐아미노치환 비시클로환계 히드록삼산 유도체
ES2272383T3 (es) Uso de un agente que mejora la funcion astrocitica para el tratamiento de la enfermedad de parkison.
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid